First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).
Year: 2011
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: W. R. Schelman, S. K. Sandhu, V. Moreno Garcia, G. Wilding, L. Sun, C. Toniatti, M. Stroh, N. Kreischer, C. L. Carpenter, L. R. Molife, S. B. Kaye, J. S. De Bono, R. M. Wenham
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2276971282